More exciting data is being presented today at EASD 2023 by our collaborators. In both studies, advanced imaging techniques were used to assess and measure various treatment effects in patients with type 2 diabetes (T2D).
James Goodman (Department of Medicine, University of Cambridge) will be presenting the initial data from a study looking at the effects of dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonism on the cardiovascular system using [18F]-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI). This mechanistic study assessed the effects on both myocardial function and myocardial glucose uptake in overweight patients with type 2 diabetes (T2). The study was a collaboration between the University of Cambridge, AstraZeneca, and Antaros Medical.
Aino Latva-Rasku (Turku PET Centre) will be presenting data on behalf of a collaboration between Turku PET Centre, AstraZeneca, and Antaros Medical. In this study, [18F]-6-this-heptadecanoic acid (FTHA) PET was used to look at the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition on fatty acid metabolism in skeletal muscle, the brain, and the small intestine in patients with T2D.
You can find the abstract details for both below.
Title: A pilot study using [18F]FDG PET/MRI to investigate dual GLP-1 and glucagon receptor agonism on myocardial glucose uptake and myocardial function in adults with type 2 diabetes
Abstract number: 646
Authors: Goodman JDH, Schain M, Lupson V, Horn T, Manavaki R, Fryer TD, Di Stefano G, Amiss E, Jalaludeen N, Haraldsson H, Jermutus L, Cgeriyan J, Johansson L, Ambery P, Wilkinson IB
Session: SO 45 – Dual agonism: two of us
Short oral discussion Wednesday, October 4 12:45-13:45 CEST
Title: SGLT2 inhibitor dapagliflozin increases skeletal muscle and brain fatty acid uptake in subjects with type 2 diabetes – a positron emission tomography study
Abstract number: 133
Authors: Latva-Rasku A, Tuisku J, Bhowmik A, Keskinen H, Rebelos E, Laurila S, Koffert J, Nummenmaa L, Heurling K, Oscarsson J, Nuutila P
Session: OP 23 – More news from SGLT2s
Oral presentation Wednesday, October 4 15:30-15:45 CEST